Comparative Pharmacology
Head-to-head clinical analysis: GLYRX PF versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYRX PF versus HICON.
GLYRX-PF vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic that inhibits muscarinic acetylcholine receptors, thereby reducing salivary secretion and blocking vagally mediated bronchoconstriction.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Intravenous: 1 mg/kg of ideal body weight for 2 minutes, repeated in 2 hours if required; thereafter every 4 hours as needed.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life of 4-6 hours; prolonged to 10-12 hours in renal impairment.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (70-80%) and metabolites; minor biliary excretion (<10%).
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic